Randy Brenner has been Paratek’s Chief Development and Regulatory Officer since June 2019. Since 2015, Mr. Brenner has been part of the Executive team leading the regulatory, quality and manufacturing activities for NUZYRA’s development and approval.
Prior to Paratek, Mr. Brenner was the Global Head of Regulatory Affairs at Shire Pharmaceuticals where he was responsible for all aspects of regulatory for a broad range of programs in multiple therapeutic areas and pharmaceutical technologies. Before that, Mr. Brenner was Head of Regulatory Affairs for the Emerging Markets and Established Products Business Units at Pfizer. In this role, he played an active part on the regional leadership teams and was responsible for the regulatory activities and staff leading the development, registration, launch, and life cycle of all of Pfizer's innovative products outside the United States and European Union as well as the Established Products business in all regions.
Prior to Pfizer, Mr. Brenner spent 14 years at Wyeth Pharmaceuticals, where he held multiple senior regulatory positions.
Mr. Brenner has a B.S. in Chemistry from Muhlenberg College and an M.S. in Pharmaceutical Sciences from Temple University.
.svg)
Passion, accountability, and collaboration. At Paratek, we count on each other to build a company that saves lives. Learn more about life @Paratek.
Explore Careers.png)
